Strategies to Improve Antineoplastic Activity of Drugs in Cancer Progression

doi:10.3390/books978-3-0365-5927-8

Format

Hardback

License and Copyright

Keywords

EGR-1; flavonoid; (E)-5-((4-oxo-4H-chromen-3-yl)methyleneamino)-1-phenyl-1H-pyrazole-4-carbonitrile; MDA-MB-231; MMP9; TNFα; pancreatic ductal adenocarcinoma; cyclodextrin inclusion complex; phase solubility studies; preformulation studies; biphenylnicotinamide derivatives; dual inhibitor; EGFR; VEGFR2; ligand-based pharmacophore; molecular docking; molecular dynamics; leukemias; doxorubicin; inflammation; drug delivery; tumor targeting; elastin-like polypeptide; cell penetrating peptide; matrix metalloproteinase; doxorubicin resistance; photosensitizer delivery system; PAMAM dendrimer; photodynamic therapy; cytotoxicity; phototoxicity; colorectal adenocarcinoma; dicarboximides; chemical synthesis; cytotoxicity; apoptosis; kinases; anticancer; gene profiling; SAR; biomarkers; colorectal cancer; early detection examination; liquid biopsy; personalized medicine; tumor treatment; exosomes; ctDNA; CTC; cytotoxic activity; pyrazole derivatives; MTT assay; ADMET analysis; single-crystal diffraction; FTIR spectroscopy; NMR spectroscopy thermogravimetric analysis; acute myelogenous leukemia; platelets; microparticles; apoptosis; γδ T cells; immunotherapy; tumor resistance; combination therapy; tumor microenvironment; immune checkpoint inhibitor; neuroblastoma; molecular iodine; cyclophosphamide; xenografts; metronomic therapy; tamoxifen; CYP2D6; MCF-7; Ishikawa cells; SERM; TNBC; uterotrophic; α-mangostin; poly(amidoamine) dendrimer; targeted drug delivery; biotin targeting; glioblastoma multiforme; squamous cell carcinoma; antiparasitic therapy; diclofenac; indomethacin; oleanolic acid derivative conjugates; NF-κB; Nrf2; MAPKs; PSN-1 cells; inflammation; reactive oxygen species; glioblastoma; brain tumor; drug delivery; extracellular vesicles; pancreatic cancer; paclitaxel; clathrin; endocytosis; sulforaphane; nicotine; metalloproteinase-9; gastric cancer; cell invasion; Arylquin 1; colon cancer; tumor progression; apoptosis; azelastine; oxidative stress; autophagy; apoptosis; mitotic catastrophe; chronic myeloid leukemia; imatinib; tyrosine kinase; ketoconazole; P-glycoprotein; drug efflux transporter; non-small-cell lung cancer; cisplatin resistance; aldehyde dehydrogenase; isothiocyanates; disulfiram; epithelial to mesenchymal transition; aminopeptidase N; acetamidophenones; Schiff bases; semicarbazones; thiosemicarbazones; inhibition of proliferation

Reprint

Download Flyer

Strategies to Improve Antineoplastic Activity of Drugs in Cancer Progression

Edited by

December 2022

416 pages

ISBN978-3-0365-5928-5 (Hardback)
ISBN978-3-0365-5927-8 (PDF)

https://doi.org/10.3390/books978-3-0365-5927-8

Free Download (PDF)

This is a Reprint of the Special Issue Strategies to Improve Antineoplastic Activity of Drugs in Cancer Progression that was published in

Biology & Life Sciences

Chemistry & Materials Science

Medicine & Pharmacology

Summary

The aim of this Special Issue is to collect reports regarding all the recent strategies, directed at the improvement of antineoplastic activity of drugs in cancer progression, engaging all the expertise needed for the development of new anticancer drugs: medicinal chemistry, pharmacology, molecular biology, and computational and drug delivery studies.

Related Books

July 2023

March 2023

Novel Anticancer Strategies

Medicine & Pharmacology

Strategies to Improve Antineoplastic Activity of Drugs in Cancer Progression

Related Books

Recent Advances of Novel Pharmaceutical Designs for Anti-cancer Therapies

Anticancer Drugs 2021

Anticancer Drugs

Anticancer Drugs Activity and Underlying Mechanisms

Novel Anticancer Strategies